Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost
30.6.2026 16:13:00 CEST | Business Wire | Press Release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions.
General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, grounded in an expert-verified knowledge base, wins on all three at once.
Accuracy: 90% fewer wrong answers
On the same 55 documents, the general-purpose LLM was wrong 56% of the time. Confidence made it worse, not better. Of the answers it rated high confidence, 35% were still wrong. With Archer Evolv, more than 95% of determinations are verified outright, and the rest are routed to an expert before use. Not a single wrong date reached production. Nothing ships unverified.
Outcome on the sample documents | Generic LLM process | Archer Evolv |
Correct | 44% | 95% verified, 5% expert-checked |
Wrong, returned as valid | 25% | 0% |
Failed or timed out | 31% | 0% |
A model's own confidence is not a control. Of the answers the general purpose LLM rated high confidence, 35% were wrong. That accuracy gap is the precondition for deploying agentic AI responsibly, because an autonomous operator is only as trustworthy as the determinations beneath it. Verified, source-traceable, expert-governed answers make it possible to safely deploy AI agents across an enterprise. This is the core of AI governance, and the layer Archer is built to provide.
“In compliance, an answer that is fast and cheap, but wrong, is worthless, and an answer you cannot trace is a liability," said Kayvan Alikhani, Chief Product and Technology Officer of Archer. "Archer's purpose-built AI verified more than 95% of determinations in real time. That is the foundation that lets enterprises scale AI agents without losing control of the outcome."
Speed: verified answers in real time
Per request, the general-purpose process averaged about four seconds per response within a five-second timeout. Archer Evolv served a verified date in roughly five-hundredths of a second, about 80 times faster on repeat lookups. For AI agents and analysts working at the pace of a regulatory calendar, that is the difference between keeping up and becoming the bottleneck.
Cost: a persistent, verified knowledge base, not on-demand inference
A general-purpose process recomputes the answer on every request, with no memory of what it found before. Archer Evolv computes once at ingestion, verifies the result into a scalable, expert-governed knowledge base, and persists it for every future lookup at a fraction of the cost and latency. When a regulation is amended, Evolv catches the change proactively, re-verifies, and versions the updated answer. Nothing served is ever stale. For a 500-document corpus with 12 lookups each per month, that is 6,000 determinations against only 500. Archer Evolv avoids roughly 92% of the inference calls, a structural saving that widens as volume grows.
Context is what makes this possible
Archer Evolv's advantage traces to context: before any AI runs, it assesses the organization's jurisdictions, products, business units, risks and regulatory themes, so every determination is grounded in what is relevant to that enterprise. This is the difference between an answer and a defensible answer. The more agents a company deploys, the more valuable that foundation becomes, because every agent inherits the same verified, source-traceable grounding rather than re-deriving the world from scratch.
"The companies that win the next decade of SaaS will pair domain-specific AI with proprietary, vertical-specific context the foundation models cannot replicate," said Bill Diaz, Chief Executive Officer of Archer. "That is the moat, and it compounds. This test is the proof."
The full methodology, source data and case study are available on Archer’s thought leadership website, compliance.ai/evolv_assets/case-01-evolv-vs-raw-llm.html. To see Archer Evolv in action, visit www.archerirm.com.
About Archer
Archer powers how the world's leading enterprises govern risk, compliance, and regulatory change. More than 1,300 organizations run on Archer, including half the Fortune 500 and 37 of the top 50 global banks. A new regulatory change lands somewhere in the world every six minutes, and agentic AI is outpacing most teams' ability to govern it. Archer's purpose-built AI is grounded in the deepest regulatory data and domain expertise in GRC, so every result traces back to its source, and every decision can be defended. Archer delivers solutions across the full range of GRC, including regulatory change management, AI risk management, regulatory intelligence, third-party risk, and IT and security risk. Learn more at www.archerirm.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260630423261/en/
Contacts
Kevin Bobowski
kevin.bobowski@archerirm.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press Release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press Release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press Release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press Release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press Release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom